Molecular Beacon Nanoparticles for Direct CTC Detection
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for detecting circulating tumor cells in blood are invasive, prone to false results, and damage cells during enrichment, with existing nanomaterials having poor biocompatibility and limited ability to detect nucleic acid expression in real-time.
Innovation Solution
A molecular beacon delivery system using self-assembled nanoparticles composed of protamine and a molecular beacon, functionalized with aptamers, which target and enter circulating tumor cells, releasing the beacon to detect nucleic acid changes in real-time through fluorescence recovery.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If cell enrichment methods (density gradient centrifugation, magnetic-activated cell sorting) are used to detect CTCs, then detection sensitivity is improved, but CTCs are easily damaged during enrichment and the process becomes cumbersome
Solution Approach 1:
Instead of enriching cells first then detecting them (conventional approach), the patent inverts the sequence by detecting CTCs directly in blood samples without enrichment. The molecular beacon system detects nucleic acid markers on CTCs in situ, eliminating the need for damaging enrichment steps while maintaining detection sensitivity.
Solution Approach 2:
The patent extracts the detection function from the enrichment process by using molecular beacons that can detect CTCs directly in the blood matrix. This separates detection from enrichment, allowing detection to occur without the harmful mechanical and chemical stresses of enrichment procedures.
2Measurement precision
If enrichment before characterization is used, then CTC detection capability is improved, but living cells cannot be detected in real time and the process becomes overly dependent on staining methods
Solution Approach 1:
The patent inverts the conventional enrichment-then-characterization sequence by implementing detection-then-enrichment. Molecular beacons detect CTCs in real-time in living blood samples, and only after detection are cells enriched if needed for further analysis. This preserves real-time detection capability and eliminates dependency on staining methods.
Solution Approach 2:
The patent replaces mechanical enrichment methods with a molecular recognition system. Molecular beacons use nucleic acid hybridization to detect CTCs, substituting mechanical separation with chemical recognition, enabling real-time detection without physical manipulation of cells.
3Productivity
If metal or inorganic non-metal nanomaterials are used for CTC detection, then detection efficiency is improved, but biocompatibility is poor
Solution Approach 1:
The patent uses composite nanomaterials combining organic molecular beacons with inorganic fluorescent labels. The molecular beacon portion provides biocompatible nucleic acid recognition, while the fluorescent label provides detection capability. This composite structure achieves both high detection efficiency and excellent biocompatibility.
Solution Approach 2:
The molecular beacon acts as an intermediary between biocompatible nucleic acid sequences and fluorescent detection signals. The beacon consists of a biocompatible nucleic acid region that binds to target sequences on CTCs, linked to a fluorescent label that provides detection capability, thus mediating between biocompatibility and detection efficiency.
4Measurement precision
If antibodies or aptamers are used to detect CTC surface proteins, then surface antigen detection is improved, but nucleic acid molecules inside cells cannot be detected
Solution Approach 1:
The molecular beacon system provides multi-functionality by being able to detect both surface proteins (through aptamer-functionalized beacons) and intracellular nucleic acids (through nucleic acid hybridization). A single platform achieves both detection capabilities, eliminating the need for separate antibody-based and nucleic acid-based detection systems.
Solution Approach 2:
The patent changes the detection parameter from surface protein recognition to intracellular nucleic acid recognition. Molecular beacons can hybridize with nucleic acid sequences inside CTCs, providing direct access to genetic information that antibodies cannot detect, while maintaining the ability to detect surface markers through aptamer-functionalized beacons.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The system enables efficient, non-invasive detection of circulating tumor cells with real-time monitoring of nucleic acid changes, avoiding cell damage and using biocompatible materials, thus improving early cancer detection and treatment guidance.
Implementation Method 1
The molecular beacon is in a state of fluorescence quenching through fluorescence resonance energy transfer
Implementation Method 2
Aptamers on the surface of the nanoparticles can bind with protein overexpressed on the surface of the circulating tumor cells
Implementation Method 3
The nanoparticles enter the cells through active targeting endocytosis
Data Source
AI summary
A molecular beacon delivery system for directly detecting circulating tumor cells in blood, comprising nanoparticles self-assembled by a polymer material, protamine, and a molecular beacon.